Northland Capmk Analyzes BioLife Solutions Q4 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) has recently come under the spotlight as analysts from Northland Capmk have made predictions regarding the company's financial performance. In a research note published on January 8th, analyst C. Byrnes projected that BioLife Solutions will report earnings per share (EPS) of $0.00 for the fourth quarter of 2025. This expectation contrasts with the consensus estimate for the full year, which currently stands at a loss of $0.29 per share for 2025. Furthermore, Northland Capmk has forecasted earnings of $0.10 per share for BioLife Solutions in the fiscal year 2026.

In addition to Northland Capmk's projections, several other financial institutions have weighed in on BioLife Solutions. KeyCorp has recently raised its price target on the company’s shares from $30.00 to $33.00, while maintaining an "overweight" rating in their report dated December 13th. Benchmark also reaffirmed a "buy" rating with a target price of $30.00 in their evaluation released on December 19th. TD Cowen has increased its price objective for BioLife Solutions from $28.00 to $31.00 with a "buy" rating, while HC Wainwright revised their target price down from $29.00 to $27.00 but maintained a "buy" stance. Craig Hallum also increased their price target to $32.00 from the previous $30.00, asserting a "buy" rating.

Stock Performance Overview

As of the opening on Friday, the stock price for BioLife Solutions stood at $27.69. The company has a fifty-day moving average price of $25.99 and a two-hundred-day moving average price of $24.29. Over the past year, BioLife Solutions’ stock has experienced a significant range, with a low of $14.50 and a high of $28.88, and currently boasts a market capitalization of $1.28 billion. The company’s PE ratio is reported at -26.12 with a beta of 1.92, indicating relatively high volatility. Moreover, the company’s financial health is evident in its debt-to-equity ratio of 0.03, a quick ratio of 1.78, and a current ratio of 2.78.

Institutional Trading Activity

Recent trades by institutional investors indicate a growing interest in BioLife Solutions. Mark Sheptoff Financial Planning LLC established a new stake worth approximately $28,000 during the third quarter. Quest Partners LLC also purchased nearly $57,000 worth of shares. Additionally, GAMMA Investing LLC increased its holdings by 29.4% in the same quarter, now owning 3,295 shares valued at about $83,000 post-acquisition. Canada Pension Plan Investment Board invested around $122,000 for a new position in the stock, while Summit Global Investments acquired shares worth approximately $228,000 during the third quarter. Notably, institutional investors collectively own around 93.24% of the stock.

Insider Transactions

In company insider news, CFO Troy Wichterman sold 987 shares of BioLife Solutions on January 6th at an average price of $27.02, totaling approximately $26,668.74. After this transaction, he continues to own 121,779 shares valued at around $3.29 million. Additionally, EVP Aby J. Mathew divested 10,000 shares on October 15th at an average price of $23.28, amounting to $232,800. This action resulted in a decrease in his holdings to 317,716 shares valued at approximately $7.40 million. In total, insiders have sold 113,129 shares over the past 90 days, representing about 2.20% of the stock's ownership.

Company Overview

BioLife Solutions, Inc. specializes in developing, manufacturing, and marketing bioproduction tools and services tailored for the cell and gene therapy industry, with operations extending across the United States, Europe, the Middle East, and Africa. The company’s products support both basic and applied research, as well as commercial production of biologic-based therapies.

BioLife, Analysis, Earnings